PitchSend

argenx SE Investor Day Presentation Deck

Conclusions ~41K bullous pemphigoid patients in U.S. IgG autoantibodies against BP180/BP230 are hallmark of bullous pemphigoid argenx Preclinical and clinical evidence links IgG autoantibody level to disease activity Robust Phase 2 PoC data for efgartigimod in pemphigus lead to bullous pemphigoid Phase 3 trial design Second registrational trial in skin franchise to start in parallel to ongoing pemphigus trial 46

View entire presentation